TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Nuclear export inhibitors

Inhibition of nuclear export is broadly applicable to the field of hemato-oncology. Exportin 1 (XPO1) is the nuclear transporter exporting most tumor suppressor and growth regulatory factors, and is upregulated in many malignancies conferring a poor prognosis. XPO1 inhibition, with selective inhibitors of nuclear transport (SINE), can inhibit proliferation and promote apoptosis.

Nuclear export inhibitors

Filter by content:

All Therapeutics